Translational research is the basis for the testing performed at Metropolis Laboratories. We are committed to the adoption of the latest technologies in order to provide the highest quality and most cost-effective testing services to meet clinical needs. A reference lab needs have an exhaustive test menu and it is important to add new tests whenever there is a demand due to increased awareness. Some of these tests give an added value to the organization and an edge over the peer labs.
The R&D division plays a major role in fulfilling these ever growing demands by evaluating and coordinating the overall developmental activities related to new tests and technologies. We have the expertise to create, implement and validate clinical tests across a wide range of technologies, including PCR, Real Time PCR, and DNA Sequencing etc.
Our expertise includes:
- Development of assays based on the analysis of DNA or RNA extracted from formalin-fixed, paraffin-embedded (FFPE) tissue
- Tumor enrichment protocols using macrodissection
- Rapid screening for mutations using ARMS PCR, high resolution melting curve analyses, DNA Sequencing, Primer Extension assay by SnapShot or minisequencing etc.
- Building panels for multiplexed oncogene mutation screening, mutation testing for neurological diseases.
The new test development procedure involves thorough literature search, technology evaluation, establishing a reference range if required and preparation of flyers and brochures to educate the doctors.
Two key features of the test developed at Metropolis are use of latest technology and cost effectiveness.
The team closely monitors the recent developments in the field of diagnostics and takes the charge of developing and eventually offering them to the patients.
R&D also plays a role in imparting the domain knowledge to the biotechnology students through training programs and projects.